よし兄　Yoshi

Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobacco. aacrjournals.org/clincancerres/…

Preclinical characterization and phase 1 results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate, in patients with advanced solid tumors - Annals of Oncology annalsofoncology.org/article/S0923-…

Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies lungcancerjournal.info/article/S0169-…

Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis | New England Journal of Medicine nejm.org/doi/full/10.10…

Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non–Small Cell Lung Cancer: Results From the Phase II TRUST-I Study | Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

Repurposing payloads: next generation of antibody–drug conjugates: Trends in Cancer cell.com/trends/cancer/…

Tumor-Infiltrating Clonal Hematopoiesis and Pan-Cancer Prognosis in Patients With Solid Tumors jamanetwork.com/journals/jamao…

A Roadmap to Transform Lung Cancer Outcomes: Priorities in Biology, Therapeutic Innovation, Early Detection, Prevention, and Interception aacrjournals.org/cancerdiscover…

To Stop or Not to Stop: Is It Time to Reevaluate Immunotherapy Duration in Advanced/Metastatic NSCLC? - Clinical Lung Cancer clinical-lung-cancer.com/article/S1525-…

Advances in RAS Therapeutics for Pancreatic Cancer | New England Journal of Medicine nejm.org/doi/full/10.10…

Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC–ESTRO OligoCare consortium - The Lancet Oncology thelancet.com/journals/lanon…

Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade aacrjournals.org/cancerdiscover…

First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer | New England Journal of Medicine nejm.org/doi/full/10.10…

Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report - Journal of Thoracic Oncology jto.org/article/S1556-…

Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non–Small Cell Lung Cancer: Results From the Phase II TRUST-I Study | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

The Optimization of Radiotherapy in Lung Cancer Treatment: 20 Years of Progress - Journal of Thoracic Oncology jto.org/article/S1556-…

First-line integration of Local Ablative Therapy (LAT) with EGFR Tyrosine Kinase Inhibitors (TKIs) in advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis - Journal of Thoracic Oncology jto.org/article/S1556-…

Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding aacrjournals.org/cancerdiscover…

Mutant KRAS Suppresses DNA Sensing by Remodeling Membrane Tension to Clear Extracellular Tumor DNA aacrjournals.org/cancerres/arti…